Evidence map›Paper›PMID 42871660›Full record

ArticleAME case reports2026

Pralsetinib-induced interstitial pneumonitis in a patient with metastatic pulmonary sarcomatoid carcinoma harboring

Jing Zhang, Jie Huang, Xin Li, Yao Qiu, Jingjing Xiang, Shenglin Ma, Xueqin Chen

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in AME case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Jing ZhangDepartment of Thoracic Oncology, Hangzhou Cancer Hospital, Affiliated Hangzhou First People's Hospital, Westlake University School of Medicine, Hangzhou, China.
Jie HuangDepartment of Thoracic Oncology, Hangzhou Cancer Hospital, Affiliated Hangzhou First People's Hospital, Westlake University School of Medicine, Hangzhou, China.
Xin LiDepartment of Thoracic Oncology, Hangzhou Cancer Hospital, Affiliated Hangzhou First People's Hospital, Westlake University School of Medicine, Hangzhou, China.
Yao QiuDepartment of Thoracic Oncology, Hangzhou Cancer Hospital, Affiliated Hangzhou First People's Hospital, Westlake University School of Medicine, Hangzhou, China.
Jingjing XiangDepartment of Pathology, Affiliated Hangzhou First People's Hospital, Westlake University School of Medicine, Hangzhou, China.
Shenglin MaDepartment of Thoracic Oncology, Hangzhou Cancer Hospital, Affiliated Hangzhou First People's Hospital, Westlake University School of Medicine, Hangzhou, China.
Xueqin ChenDepartment of Thoracic Oncology, Hangzhou Cancer Hospital, Affiliated Hangzhou First People's Hospital, Westlake University School of Medicine, Hangzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Pulmonary sarcomatoid carcinoma (PSC), an exceptionally rare subtype of non-small cell lung cancer (NSCLC), remains poorly characterized in terms of molecular alterations, rendering targeted therapy a promising option. Case Description: This report describes a 60-year-old male who presented with progressive hemoptysis. Bronchoscopic biopsy, combined with pathological evaluation, immunohistochemical staining, and next-generation sequencing (NGS), confirmed the diagnosis of metastatic PSC (favor spindle cell type, cT4N2M1a, stage IVa) harboring a Conclusions: Pralsetinib is effective for

Indexed as

case reportinterstitial pneumonitispralsetinibPulmonary sarcomatoid carcinoma (PSC)RET fusion

Identifiers

PMID42871660
PMCPMC13659157

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.